Idexx Laboratories Inc. (NASDAQ:IDXX) shares reached a new 52-week high during trading on Monday . The stock traded as high as $114.19 and last traded at $114.09, with a volume of 313,300 shares traded. The stock had previously closed at $113.16.

Several research analysts have recently commented on the company. Zacks Investment Research raised Idexx Laboratories from a “hold” rating to a “buy” rating and set a $106.00 price target for the company in a research report on Monday, July 25th. Canaccord Genuity reissued a “buy” rating and issued a $120.00 price target on shares of Idexx Laboratories in a research report on Monday, August 22nd. Stifel Nicolaus reissued a “buy” rating and issued a $120.00 price target (up from $92.00) on shares of Idexx Laboratories in a research report on Wednesday, August 3rd. Finally, Northcoast Research raised Idexx Laboratories from a “sell” rating to a “neutral” rating in a research report on Wednesday, August 3rd. Three investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $105.20.

The stock’s 50-day moving average is $104.98 and its 200 day moving average is $88.81. The firm has a market cap of $10.22 billion and a P/E ratio of 51.72.

Idexx Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Tuesday, August 2nd. The company reported $0.74 EPS for the quarter, topping the consensus estimate of $0.62 by $0.12. The firm had revenue of $467 million for the quarter, compared to analysts’ expectations of $444.83 million. During the same quarter in the prior year, the business earned $0.60 earnings per share. The company’s quarterly revenue was up 12.9% on a year-over-year basis. On average, equities research analysts predict that Idexx Laboratories Inc. will post $2.36 earnings per share for the current fiscal year.

In other news, Chairman Jonathan W. Ayers sold 60,000 shares of the firm’s stock in a transaction on Thursday, August 4th. The stock was sold at an average price of $107.69, for a total transaction of $6,461,400.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Rebecca M. Henderson sold 9,924 shares of the firm’s stock in a transaction on Thursday, August 25th. The stock was sold at an average price of $110.43, for a total value of $1,095,907.32. Following the transaction, the director now owns 16,678 shares of the company’s stock, valued at $1,841,751.54. The disclosure for this sale can be found here.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.